Antiverse is a techbio company designing antibodies for challenging drug targets like G-protein-coupled receptors (GPCRs) and ion channels.
Embedded in cell membranes, GPCRs are difficult to purify– an essential step required to design antibodies against them. Despite the importance (GPCRs make up a third of all FDA-approved drugs) of these targets in medicine, only a few GPCR-targeting antibodies exist, three to be exact!
Antiverse’s generative AI design platform has a novel way of designing antibodies against difficult targets and is striving to bring critical therapies to patients. With its latest funding round the company is expanding its team and facilities, enhancing its platform, and pushing forward key internal assets towards clinical trials.
Antiverse’s technology uses generative AI to design antibodies for difficult-to-target GPCRs and ion channels. Using structural and sequence data of the target, the platform designs a library of novel antibodies tailored towards the target of interest.
Antiverse then takes these antibodies for laboratory testing. If the library fails, the data can be fed back to its platform for multiple cycles until functional binders are found. Their computational approach accelerates the antibody discovery process to just six months, allowing for faster development of treatments for conditions that have remained elusive to traditional research.
invested
total equity financing raised to date
into new facilities in Boston and Prague to support growth and research
“Since the inception of Antiverse, UKI2S’ investments, strategic follow-ons, and non-dilutive contributions have fueled our growth, while proactive investor connections set us up for success in future rounds. We are profoundly grateful for their partnership and belief in our potential.”
“Antiverse is tackling a big challenge by using advanced technology to create more effective antibodies. What sets them apart is their goal to design antibodies for especially difficult diseases—ones that traditional methods struggle to treat because we can’t easily drug them. This could lead to new treatments for diseases that have previously been considered untreatable, offering hope to many patients facing serious health conditions.”
UKI2S is excited to support Antiverse as they use cutting-edge AI to unlock new treatments for some of the hardest-to-target conditions, with potential to transform patients’ lives. In addition to the £600,000 investment, UKI2S has provided co-investment introductions and strategic support, helping Antiverse expand its platform and capabilities.
Antiverse’s AI-powered approach represents a significant leap forward in antibody design, accelerating the process of bringing life-saving treatments to patients. With its innovative platform and strategic backing from UKI2S and other investors, Antiverse is poised to transform drug discovery for challenging targets, delivering hope for patients worldwide.
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, t/a Midven, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.
